Regeneron Pharmaceuticals, Inc. (REGN) has observed notable interest from numerous investors.
Wealthfront Advisers LLC,
Varma Mutual Pension Insurance Co, and
LSV Asset Management have acquired substantial stakes in REGN, displaying great faith in its potential. The biotech firm witnessed a certain degree of share selling, including transations by the significant management member such as Director and SVP cashing out. Despite this, the overall
accumulative activity continues, with new and existing investors like Krilogy Financial LLC, Skylands Capital LLC, and Savant Capital LLC adding to their holdings. Wall Street Zen and Guggenheim have upgraded REGN to 'Buy' status, affirming the market's bullish sentiment. The company's
positive results from various late-stage trials, an increase in dividends to $0.94 per share, and the advancement of their drug, REGN7508 into Phase 3 for tackling cancer-linked blood clots have positively impacted investor perspectives. Though certain management sell-offs and margin slippages present cautionary notes, the overall optimism around the firm's accomplishing REGN stock remains robust.
Regeneron Pharmaceuticals REGN News Analytics from Tue, 26 Aug 2025 07:00:00 GMT to Sat, 14 Feb 2026 12:13:22 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor -5
